Nine drugmakers join Trump’s most-favored-nation pricing initiative
Nine additional pharmaceutical manufacturers have signed onto President Donald Trump’s most-favored-nation drug pricing agreement, part of the administration’s effort to lower prescription costs.
Nine more companies have joined President Donald Trump’s most-favored-nation drug pricing agreement, one of the administration’s most publicized efforts to bring down prescription drug costs. The additions expand participation in the initiative aimed at securing lower prices for medications.